Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 29 04:00PM ET
0.4010
Dollar change
0.0000
Percentage change
0.00
%
Index- P/E- EPS (ttm)-0.43 Insider Own8.69% Shs Outstand48.08M Perf Week-0.99%
Market Cap19.58M Forward P/E- EPS next Y-0.45 Insider Trans1.35% Shs Float44.60M Perf Month-6.77%
Income-20.77M PEG- EPS next Q-0.12 Inst Own8.50% Short Float0.97% Perf Quarter-8.86%
Sales0.19M P/S103.08 EPS this Y-15.00% Inst Trans-3.70% Short Ratio3.12 Perf Half Y-41.03%
Book/sh0.45 P/B0.89 EPS next Y2.17% ROA-56.04% Short Interest0.43M Perf Year-22.93%
Cash/sh0.46 P/C0.87 EPS next 5Y25.00% ROE-63.63% 52W Range0.38 - 0.75 Perf YTD-8.84%
Dividend Est.- P/FCF- EPS past 5Y49.85% ROI-89.76% 52W High-46.44% Beta-0.12
Dividend TTM- Quick Ratio4.82 Sales past 5Y-14.54% Gross Margin-140.93% 52W Low5.80% ATR (14)0.03
Dividend Ex-Date- Current Ratio4.82 EPS Y/Y TTM1.42% Oper. Margin-12160.01% RSI (14)45.54 Volatility4.00% 6.76%
Employees24 Debt/Eq0.03 Sales Y/Y TTM44.03% Profit Margin-10764.25% Recom1.00 Target Price2.75
Option/ShortNo / Yes LT Debt/Eq0.02 EPS Q/Q-21.01% Payout- Rel Volume0.00 Prev Close0.40
Sales Surprise91.67% EPS Surprise-41.22% Sales Q/Q119.05% EarningsNov 15 BMO Avg Volume139.16K Price0.40
SMA20-2.73% SMA50-7.91% SMA200-21.37% Trades Volume0 Change0.00%
Feb-29-24 08:45AM
Feb-14-24 08:55AM
Feb-08-24 08:50AM
Jan-24-24 09:10AM
Jan-22-24 08:55AM
08:45AM Loading…
Jan-10-24 08:45AM
Jan-05-24 01:32PM
Jan-03-24 04:05PM
Dec-29-23 08:00AM
Nov-28-23 04:30PM
Nov-27-23 09:00PM
Nov-21-23 12:00PM
Nov-16-23 08:45AM
Nov-15-23 07:30AM
Nov-14-23 10:00AM
08:05AM Loading…
Nov-09-23 08:05AM
Nov-08-23 08:45AM
Nov-06-23 09:25AM
Oct-30-23 08:55AM
Oct-17-23 08:45AM
Sep-22-23 09:05AM
Sep-11-23 01:00PM
Sep-05-23 09:05AM
Aug-23-23 08:00AM
Aug-15-23 06:45AM
Aug-09-23 09:05AM
Aug-08-23 08:05AM
Jul-18-23 07:30PM
06:53AM
Jul-10-23 08:05AM
08:35AM Loading…
Jul-05-23 08:35AM
Jun-27-23 11:16AM
08:45AM
Jun-14-23 08:45AM
Jun-12-23 08:45AM
Jun-07-23 07:11PM
May-15-23 08:45AM
May-09-23 08:50AM
08:46AM
Apr-20-23 03:56PM
Apr-12-23 08:35AM
07:30AM
Apr-10-23 07:30AM
Apr-04-23 08:45AM
Apr-03-23 06:30AM
Mar-30-23 08:45AM
Mar-27-23 09:05AM
Mar-16-23 08:45AM
07:00AM
07:00AM
Mar-08-23 08:45AM
Mar-06-23 08:45AM
Feb-28-23 08:45AM
Feb-17-23 08:55AM
Jan-17-23 08:45AM
Jan-11-23 01:00PM
Jan-09-23 08:05AM
Jan-05-23 08:45AM
Dec-12-22 09:00AM
Dec-08-22 08:05AM
Dec-02-22 10:45AM
Nov-15-22 07:00AM
Nov-14-22 07:00AM
Nov-09-22 09:00AM
Nov-03-22 12:34PM
Nov-02-22 07:05AM
Nov-01-22 05:19PM
Oct-31-22 07:30AM
Oct-26-22 05:12PM
Oct-24-22 08:30AM
Oct-13-22 10:32AM
Oct-12-22 04:32PM
Sep-21-22 08:45AM
Sep-19-22 08:05AM
Sep-07-22 07:25AM
Sep-06-22 07:30AM
Aug-30-22 07:30AM
Aug-18-22 09:05AM
Aug-16-22 04:05PM
Aug-15-22 04:05PM
08:05AM
Jul-28-22 09:10AM
Jul-21-22 12:26PM
Jul-20-22 08:05AM
Jul-18-22 08:00AM
Jul-14-22 08:05AM
Jun-21-22 08:35AM
Jun-13-22 08:05AM
May-19-22 08:00AM
May-18-22 08:00AM
May-16-22 07:05AM
May-12-22 08:05AM
Apr-21-22 08:05AM
Apr-12-22 07:47AM
Apr-11-22 09:20AM
07:05AM
07:05AM
Apr-04-22 06:26PM
Mar-31-22 04:05PM
Mar-30-22 07:00AM
AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Equels Thomas KCEO & PresidentNov 27Buy0.4433,86115,000640,697Nov 27 12:56 PM
Equels Thomas KCEO & PresidentSep 29Buy0.4422,67610,000606,836Sep 29 03:29 PM
Equels Thomas KCEO & PresidentAug 25Buy0.678,2225,501584,160Aug 25 02:26 PM
Equels Thomas KCEO & PresidentAug 24Buy0.6714,99310,000575,938Aug 24 01:52 PM
Equels Thomas KCEO & PresidentJul 17Buy0.5916,95010,000560,945Jul 17 07:20 PM